Breaking down the barriers to cancer immunotherapy
- 1 December 2005
- journal article
- Published by Springer Nature in Nature Immunology
- Vol. 6 (12) , 1207-1210
- https://doi.org/10.1038/ni1205-1207
Abstract
Emerging insights into the mechanisms of activation and negative regulation of innate and adaptive immune cells are providing new opportunities for the development of safe and effective cancer vaccines.Keywords
This publication has 13 references indexed in Scilit:
- A proportion of patients with lymphoma may harbor mutations of the perforin geneBlood, 2005
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic MelanomaJournal of Clinical Oncology, 2005
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γThe Journal of Experimental Medicine, 2002
- CTLA-4: new insights into its biological function and use in tumor immunotherapyNature Immunology, 2002
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001
- Decreased tumor surveillance in perforin-deficient mice.The Journal of Experimental Medicine, 1996
- Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude MiceScience, 1974
- Immunology of Experimental TumorsAnnual Review of Medicine, 1964